<li>acetazolamide<p>acetazolamide increases toxicity of metformin by Other (see comment). Use Caution/Monitor. 
Comment: Decreases serum bicarbonate and induce non-anion gap, hyperchloremic metabolic acidosis.</p></li><li>albiglutide<p>albiglutide, metformin.
Either increases effects of the other by pharmacodynamic synergism. Use Caution/Monitor. Concurrent use may increase risk of hypoglycemia; monitor glucose levels.</p></li><li>amiodarone<p>amiodarone will increase the level or effect of metformin by  basic (cationic) drug competition for renal tubular clearance. Use Caution/Monitor.</p></li><li>aripiprazole<p>aripiprazole, metformin. Other (see comment). Use Caution/Monitor. 
Comment: Atypical antipsychotics have been associated with hyperglycemia that may alter blood glucose control; monitor glucose levels closely.</p></li><li>asenapine<p>asenapine, metformin. Other (see comment). Use Caution/Monitor. 
Comment: Atypical antipsychotics have been associated with hyperglycemia that may alter blood glucose control; monitor glucose levels closely.</p></li><li>atazanavir<p>atazanavir decreases effects of metformin by Other (see comment). Use Caution/Monitor. 
Comment: Reports of hyperglycemia due to insulin resistance with protease inhibitors. .</p></li><li>benazepril<p>benazepril increases toxicity of metformin by unspecified interaction mechanism. Use Caution/Monitor. Increases risk for hypoglycemia and lactic acidosis.</p></li><li>bitter melon<p>bitter melon increases effects of metformin by pharmacodynamic synergism. Use Caution/Monitor. Risk of hypoglycemia.</p></li><li>cimetidine<p>cimetidine will increase the level or effect of metformin by  basic (cationic) drug competition for renal tubular clearance. Use Caution/Monitor.</p></li><li>cinnamon<p>cinnamon increases effects of metformin by pharmacodynamic synergism. Use Caution/Monitor. Potential for hypoglycemia.</p></li><li>ciprofloxacin<p>ciprofloxacin increases effects of metformin by pharmacodynamic synergism. Use Caution/Monitor. Hyper and hypoglycemia have been reported in patients treated concomitantly with quinolones and antidiabetic agents. Careful monitoring of blood glucose is recommended.</p></li><li>clozapine<p>clozapine, metformin. Other (see comment). Use Caution/Monitor. 
Comment: Atypical antipsychotics have been associated with hyperglycemia that may alter blood glucose control; monitor glucose levels closely.</p></li><li>colesevelam<p>colesevelam increases levels of metformin by pharmacodynamic antagonism. Use Caution/Monitor.</p></li><li>darunavir<p>darunavir decreases effects of metformin by Other (see comment). Use Caution/Monitor. 
Comment: Reports of hyperglycemia due to insulin resistance with protease inhibitors. .</p></li><li>dichlorphenamide<p>dichlorphenamide, metformin.
Either increases toxicity of the other by pharmacodynamic synergism. Modify Therapy/Monitor Closely. Both drugs can cause metabolic acidosis.</p></li><li>digoxin<p>digoxin, metformin.
Either increases levels of the other by basic (cationic) drug competition for renal tubular clearance. Use Caution/Monitor. Measure serum digoxin concentrations before initiating metformin. Monitor patients who take both metformin and digoxin for possible digoxin toxicity and lactic acidosis. Reduce the digoxin and/or metformin dose as necessary.</p></li><li>dofetilide<p>dofetilide will increase the level or effect of metformin by  basic (cationic) drug competition for renal tubular clearance. Use Caution/Monitor.</p></li><li>dolutegravir<p>dolutegravir will increase the level or effect of metformin by  decreasing renal clearance. Modify Therapy/Monitor Closely. Dolutegravir inhibits the renal organic cation transporter, OCT2; when used with metformin, limit total daily dose of metformin to 1,000 mg either when starting metformin or dolutegravir; when stopping dolutegravir, adjustment of metformin dose may be necessary; monitor blood glucose when initiating concomitant use and after withdrawal of dolutegravir</p></li><li>dulaglutide<p>dulaglutide, metformin.
Either increases effects of the other by pharmacodynamic synergism. Use Caution/Monitor. Antidiabetic agents are often used in combination; dosage adjustments may be required when initiating or discontinuing antidiabetic agents.</p></li><li>exenatide injectable solution<p>exenatide injectable solution, metformin.
Either increases effects of the other by pharmacodynamic synergism. Use Caution/Monitor. Concurrent use may increase risk of hypoglycemia; monitor glucose levels.</p></li><li>exenatide injectable suspension<p>exenatide injectable suspension, metformin.
Either increases effects of the other by pharmacodynamic synergism. Use Caution/Monitor. Concurrent use may increase risk of hypoglycemia; monitor glucose levels.</p></li><li>fleroxacin<p>fleroxacin increases effects of metformin by pharmacodynamic synergism. Use Caution/Monitor. Quinolone antibiotic administration may result in hyper- or hypoglycemia. Gatifloxacin is most likely to produce dysglycemia; moxifloxacin is least likely.</p></li><li>fosamprenavir<p>fosamprenavir decreases effects of metformin by Other (see comment). Use Caution/Monitor. 
Comment: Reports of hyperglycemia due to insulin resistance with protease inhibitors. .</p></li><li>gemifloxacin<p>gemifloxacin increases effects of metformin by pharmacodynamic synergism. Use Caution/Monitor. Quinolone antibiotic administration may result in hyper- or hypoglycemia. Gatifloxacin is most likely to produce dysglycemia; moxifloxacin is least likely.</p></li><li>iloperidone<p>iloperidone, metformin. Other (see comment). Use Caution/Monitor. 
Comment: Atypical antipsychotics have been associated with hyperglycemia that may alter blood glucose control; monitor glucose levels closely.</p></li><li>indinavir<p>indinavir decreases effects of metformin by Other (see comment). Use Caution/Monitor. 
Comment: Reports of hyperglycemia due to insulin resistance with protease inhibitors. .</p></li><li>insulin aspart<p>metformin, insulin aspart.
Either increases effects of the other by pharmacodynamic synergism. Use Caution/Monitor. Antidiabetic agents are often used in combination; dosage adjustments may be required when initiating or discontinuing antidiabetic agents.</p></li><li>insulin aspart protamine/insulin aspart<p>metformin, insulin aspart protamine/insulin aspart.
Either increases effects of the other by pharmacodynamic synergism. Use Caution/Monitor. Antidiabetic agents are often used in combination; dosage adjustments may be required when initiating or discontinuing antidiabetic agents.</p></li><li>insulin degludec<p>metformin, insulin degludec.
Either increases effects of the other by pharmacodynamic synergism. Use Caution/Monitor. Antidiabetic agents are often used in combination; dosage adjustments may be required when initiating or discontinuing antidiabetic agents.</p></li><li>insulin degludec/insulin aspart<p>metformin, insulin degludec/insulin aspart.
Either increases effects of the other by pharmacodynamic synergism. Use Caution/Monitor. Antidiabetic agents are often used in combination; dosage adjustments may be required when initiating or discontinuing antidiabetic agents.</p></li><li>insulin detemir<p>metformin, insulin detemir.
Either increases effects of the other by pharmacodynamic synergism. Use Caution/Monitor. Antidiabetic agents are often used in combination; dosage adjustments may be required when initiating or discontinuing antidiabetic agents.</p></li><li>insulin glargine<p>metformin, insulin glargine.
Either increases effects of the other by pharmacodynamic synergism. Use Caution/Monitor. Antidiabetic agents are often used in combination; dosage adjustments may be required when initiating or discontinuing antidiabetic agents.</p></li><li>insulin glulisine<p>metformin, insulin glulisine.
Either increases effects of the other by pharmacodynamic synergism. Use Caution/Monitor. Antidiabetic agents are often used in combination; dosage adjustments may be required when initiating or discontinuing antidiabetic agents.</p></li><li>insulin inhaled<p>metformin, insulin inhaled.
Either increases effects of the other by pharmacodynamic synergism. Use Caution/Monitor. Antidiabetic agents are often used in combination; dosage adjustments may be required when initiating or discontinuing antidiabetic agents.</p></li><li>insulin isophane human/insulin regular human<p>metformin, insulin isophane human/insulin regular human.
Either increases effects of the other by pharmacodynamic synergism. Use Caution/Monitor. Antidiabetic agents are often used in combination; dosage adjustments may be required when initiating or discontinuing antidiabetic agents.</p></li><li>insulin lispro<p>metformin, insulin lispro.
Either increases effects of the other by pharmacodynamic synergism. Use Caution/Monitor. Antidiabetic agents are often used in combination; dosage adjustments may be required when initiating or discontinuing antidiabetic agents.</p></li><li>insulin lispro protamine/insulin lispro<p>metformin, insulin lispro protamine/insulin lispro.
Either increases effects of the other by pharmacodynamic synergism. Use Caution/Monitor. Antidiabetic agents are often used in combination; dosage adjustments may be required when initiating or discontinuing antidiabetic agents.</p></li><li>insulin nph<p>metformin, insulin nph.
Either increases effects of the other by pharmacodynamic synergism. Use Caution/Monitor. Antidiabetic agents are often used in combination; dosage adjustments may be required when initiating or discontinuing antidiabetic agents.</p></li><li>insulin regular human<p>metformin, insulin regular human.
Either increases effects of the other by pharmacodynamic synergism. Use Caution/Monitor. Antidiabetic agents are often used in combination; dosage adjustments may be required when initiating or discontinuing antidiabetic agents.</p></li><li>ketotifen, ophthalmic<p>ketotifen, ophthalmic, metformin. Other (see comment). Use Caution/Monitor. 
Comment: Combination may result in thrombocytopenia (rare).  Monitor CBC.</p></li><li>levofloxacin<p>levofloxacin increases effects of metformin by pharmacodynamic synergism. Use Caution/Monitor. Quinolone antibiotic administration may result in hyper- or hypoglycemia. Gatifloxacin is most likely to produce dysglycemia; moxifloxacin is least likely.</p></li><li>liraglutide<p>liraglutide, metformin.
Either increases effects of the other by pharmacodynamic synergism. Use Caution/Monitor. Concurrent use may increase risk of hypoglycemia; monitor glucose levels.</p></li><li>lopinavir<p>lopinavir decreases effects of metformin by Other (see comment). Use Caution/Monitor. 
Comment: Reports of hyperglycemia due to insulin resistance with protease inhibitors. .</p></li><li>lurasidone<p>lurasidone, metformin. Other (see comment). Use Caution/Monitor. 
Comment: Atypical antipsychotics have been associated with hyperglycemia that may alter blood glucose control; monitor glucose levels closely.</p></li><li>marijuana<p>marijuana decreases effects of metformin by pharmacodynamic antagonism. Use Caution/Monitor.</p></li><li>mecasermin<p>mecasermin increases effects of metformin by pharmacodynamic synergism. Use Caution/Monitor. Additive hypoglycemic effects.</p></li><li>moxifloxacin<p>moxifloxacin increases effects of metformin by pharmacodynamic synergism. Use Caution/Monitor. Quinolone antibiotic administration may result in hyper- or hypoglycemia. Gatifloxacin is most likely to produce dysglycemia; moxifloxacin is least likely.</p></li><li>nelfinavir<p>nelfinavir decreases effects of metformin by Other (see comment). Use Caution/Monitor. 
Comment: Reports of hyperglycemia due to insulin resistance with protease inhibitors. .</p></li><li>nizatidine<p>nizatidine will increase the level or effect of metformin by  decreasing renal clearance. Modify Therapy/Monitor Closely.</p></li><li>norfloxacin<p>norfloxacin increases effects of metformin by pharmacodynamic synergism. Use Caution/Monitor. Quinolone antibiotic administration may result in hyper- or hypoglycemia. Gatifloxacin is most likely to produce dysglycemia; moxifloxacin is least likely.</p></li><li>ofloxacin<p>ofloxacin increases effects of metformin by pharmacodynamic synergism. Use Caution/Monitor. Quinolone antibiotic administration may result in hyper- or hypoglycemia. Gatifloxacin is most likely to produce dysglycemia; moxifloxacin is least likely.</p></li><li>olanzapine<p>olanzapine, metformin. Other (see comment). Use Caution/Monitor. 
Comment: Atypical antipsychotics have been associated with hyperglycemia that may alter blood glucose control; monitor glucose levels closely.</p></li><li>ombitasvir/paritaprevir/ritonavir<p>ombitasvir/paritaprevir/ritonavir increases toxicity of metformin by unspecified interaction mechanism. Use Caution/Monitor. Monitor for signs of onset of lactic acidosis such as respiratory distress, somnolence, and non-specific abdominal distress or worsening renal function; concomitant metformin use in patients with renal insufficiency or hepatic impairment not recommended.</p></li><li>ombitasvir/paritaprevir/ritonavir &amp; dasabuvir<p>ombitasvir/paritaprevir/ritonavir &amp; dasabuvir increases toxicity of metformin by unspecified interaction mechanism. Use Caution/Monitor. Monitor for signs of onset of lactic acidosis such as respiratory distress, somnolence, and non-specific abdominal distress or worsening renal function;  concomitant metformin use in patients with renal insufficiency or hepatic impairment not recommended.</p></li><li>opuntia ficus indica<p>opuntia ficus indica increases effects of metformin by pharmacodynamic synergism. Use Caution/Monitor.</p></li><li>paliperidone<p>paliperidone, metformin. Other (see comment). Use Caution/Monitor. 
Comment: Atypical antipsychotics have been associated with hyperglycemia that may alter blood glucose control; monitor glucose levels closely.</p></li><li>patiromer<p>patiromer will decrease the level or effect of metformin by  drug binding in GI tract. Use Caution/Monitor. May administer  3 hours apart</p></li><li>procainamide<p>metformin will increase the level or effect of procainamide by  basic (cationic) drug competition for renal tubular clearance. Use Caution/Monitor.</p></li><li>quetiapine<p>quetiapine, metformin. Other (see comment). Use Caution/Monitor. 
Comment: Atypical antipsychotics have been associated with hyperglycemia that may alter blood glucose control; monitor glucose levels closely.</p></li><li>quinidine<p>quinidine will increase the level or effect of metformin by  basic (cationic) drug competition for renal tubular clearance. Use Caution/Monitor.</p></li><li>ranitidine<p>ranitidine will increase the level or effect of metformin by  decreasing renal clearance. Modify Therapy/Monitor Closely.</p></li><li>risperidone<p>risperidone, metformin. Other (see comment). Use Caution/Monitor. 
Comment: Atypical antipsychotics have been associated with hyperglycemia that may alter blood glucose control; monitor glucose levels closely.</p></li><li>ritonavir<p>ritonavir decreases effects of metformin by Other (see comment). Use Caution/Monitor. 
Comment: Reports of hyperglycemia due to insulin resistance with protease inhibitors. .</p></li><li>saquinavir<p>saquinavir decreases effects of metformin by Other (see comment). Use Caution/Monitor. 
Comment: Reports of hyperglycemia due to insulin resistance with protease inhibitors. .</p></li><li>shark cartilage<p>shark cartilage increases effects of metformin by pharmacodynamic synergism. Use Caution/Monitor. Theoretical interaction.</p></li><li>sulfamethoxypyridazine<p>sulfamethoxypyridazine increases effects of metformin by unspecified interaction mechanism. Use Caution/Monitor. Risk of hypoglycemia.</p></li><li>tenofovir df<p>tenofovir df increases levels of metformin by decreasing renal clearance. Use Caution/Monitor. Increased risk of lactic acidosis.</p></li><li>tipranavir<p>tipranavir decreases effects of metformin by Other (see comment). Use Caution/Monitor. 
Comment: Reports of hyperglycemia due to insulin resistance with protease inhibitors. .</p></li><li>topiramate<p>topiramate increases toxicity of metformin by Other (see comment). Use Caution/Monitor. 
Comment: Decreases serum bicarbonate and induce non-anion gap, hyperchloremic metabolic acidosis.</p></li><li>trospium chloride<p>metformin will decrease the level or effect of trospium chloride by  increasing renal clearance. Use Caution/Monitor. Coadministration reduced steady state trospium systemic exposure (decreased AUC and Cmax) by competing for renal tubular secretion</p></li><li>vandetanib<p>vandetanib increases levels of metformin by Other (see comment). Modify Therapy/Monitor Closely. 
Comment: Vandetanib inhibits the uptake of substrates of organic cation transporter type 2 (OCT2).</p></li><li>xipamide<p>xipamide decreases levels of metformin by increasing renal clearance. Use Caution/Monitor.</p></li><li>ziprasidone<p>ziprasidone, metformin. Other (see comment). Use Caution/Monitor. 
Comment: Atypical antipsychotics have been associated with hyperglycemia that may alter blood glucose control; monitor glucose levels closely.</p></li><li>zonisamide<p>zonisamide increases toxicity of metformin by Other (see comment). Use Caution/Monitor. 
Comment: Decreases serum bicarbonate and induce non-anion gap, hyperchloremic metabolic acidosis.</p></li>